Journal of Neuro-Oncology

, Volume 43, Issue 1, pp 79–86

Gossypol Treatment of Recurrent Adult Malignant Gliomas

Authors

  • Peter Bushunow
    • Department of Medicine and University of Rochester Cancer CenterUniversity of Rochester
  • Marcus M. Reidenberg
    • Departments of Pharmacology and MedicineCornell University Medical College
  • John Wasenko
    • Department of RadiologySUNY Health Science Center
  • Jeffrey Winfield
    • Department of NeurosurgerySUNY Health Science Center
  • Beverly Lorenzo
    • Departments of Pharmacology and MedicineCornell University Medical College
  • Sheila Lemke
    • Department of MedicineSUNY Health Science Center
  • Benjamin Himpler
    • Department of MedicineSUNY Health Science Center
  • Robert Corona
    • Department of PathologySUNY Health Science Center
  • Thomas Coyle
    • Department of NeurosurgerySUNY Health Science Center
    • Department of MedicineSUNY Health Science Center
Article

DOI: 10.1023/A:1006267902186

Cite this article as:
Bushunow, P., Reidenberg, M.M., Wasenko, J. et al. J Neurooncol (1999) 43: 79. doi:10.1023/A:1006267902186

Abstract

Gossypol, a polyphenolic compound which depletes cellular energy by inhibition of several intracellular dehydrogenases, has been shown to have antiproliferative activity against human glial tumor cell lines in vitro and in nude mouse xenografts. Human trials of gossypol as a male contraceptive have demonstrated safety of long-term administration. We studied the activity of Gossypol 10 mg PO bid in 27 patients with pathologically confirmed glial tumors which had recurred after radiation therapy. Fifteen patients had glioblastoma, 11 patients anaplastic astrocytoma, 1 patient relapsed low grade glioma. Response was assessed every 8 weeks using CT/MRI scan and clinical criteria including decadron requirement. Treatment was continued until disease progression. Two patients had partial response (PR); 4 had stable disease for 8 weeks or more. One patient maintained a PR with improved KPS for 78 weeks. The other had a PR lasting 8 weeks. Toxicity was mild: 2 heavily pretreated patients had mild thrombocytopenia, 5 patients developed hypokalemia, 3 patients developed grade 2 hepatic toxicity and peripheral edema. Gossypol levels measured by HPLC did not correlate with response or toxicity in this study.

We conclude that gossypol is well tolerated and has a low, but measurable, response rate in a heavily pretreated, poor-prognosis group of patients with recurrent glioma. The presumed novel mechanism of action, lack of significant myelosuppression, and activity in patients with advance glioma support further study of gossypol as an antineoplastic agent.

malignant gliomagossypollactate dehydrogenase isoenzymeschemotherapy

Copyright information

© Kluwer Academic Publishers 1999